In:
The Journal of Immunology, The American Association of Immunologists, Vol. 190, No. 1_Supplement ( 2013-05-01), p. 214.2-214.2
Abstract:
In our search for better ways to stimulate anti-tumor T cell-mediated immune response we optimized powerful technique known as “reverse” immunogenetics, in which MHC I-bound peptides are recovered and sequenced using highly sensitive mass spectrometry. Using this technique we have identified more than 3,500 peptides eluted from the surface of 20 breast carcinoma cell lines of 4 different subtypes. By using sequence data for each breast carcinoma cell line we predicted bound peptide consensus sequence for a particular allele of HLA-A, -B, and C molecules. Next, we determined the frequency of the identification of both peptide and protein that is associated with this peptide in subtype-specific and all analyzed cell lines. This allowed us to associate some MHC I-presented peptides/proteins with a specific subtype of breast cancer as well as shared peptides/proteins. Some of the identified proteins are tumor specific and immunogenic. For example, Aldolase A, which is MHC I-presented in many cell lines, has been identified by Serex analysis in lung cancer and breast cancer patients. Lastly, using gene expression data for 60 breast carcinoma and normal cell lines as well as for 708 tumors and 329 normal tissues we have sorted all identified proteins in accordance with the level of their expression in non-transformed and transformed cells. This arrangement allowed us to identify, for the first time, several tumor specific genes that could be good targets for T cell-based therapy.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.190.Supp.214.2
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2013
detail.hit.zdb_id:
1475085-5
Permalink
